Related Experiment Video
Updated: Apr 16, 2026

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
Novel Benzothiadiazine Derivatives as MRGX2 Antagonists for Treating Chronic Spontaneous Urticaria
1Arclin USA LLC, 1150 Sanctuary Parkway, Suite 100, Alpharetta, Georgia 30009, United States.
Abstract:
Provided herein are novel benzothiadiazine derivatives as Mas-related G protein-coupled receptor X2 (MRGPRX2) or MRGX2 (Mas-related Gene X2) antagonists, pharmaceutical compositions, use of such compounds in treating chronic spontaneous urticaria, and processes for preparing such compounds.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

